Tirofiban HCl
Tirofiban HCl Information
Find all the information of Tirofiban HCl medicine and drugs available in Pakistan. Read the pricing, side effects, usage, instructions and dosage of Tirofiban HCl by .
Tirofiban HCl
medicine,pricing, side effects of Tirofiban HCl medicine by company and complete information of medicines in pakistan here on this page including all packings, MG, dosage information. This list includes medicines and drugs over every region of Pakistan like Karachi, Lahore, Islamabad, Faisalabad, Rawalpindi, Multan, Peshawar, Quetta and other cities of Pakistan.About Tirofiban HCl
An antiplatelet drug and the glycoprotein IIb/IIIa inhibitor, is indicated for unstable angina in patients with a high risk of developing myocardial infarction. It is administered parenterally. It is also under investigation in patients undergoing coronary angioplasty.
Indications
Tirofiban HCl is primarily indicated in conditions like Gastric acid reduction during anaesthesia, Hyperlipidaemias, Unstable angina.
Contraindication
Tirofiban HCl is contraindicated in conditions like Thrombocytopenia,Hemorrhagic diathesis,Breast feeding,Pain management,Infections in neutropenic patients (in combination with an aminoglycoside).
Side Effects
The symptomatic adverse reactions produced by Tirofiban HCl are more or less tolerable and if they become severe, they can be treated symptomatically, these include Thrombocytopenia, Bleeding manifestation.
Warnings
Tirofiban should be used with caution in patients with hepatic impairment (avoid if severe); renal impairment; major surgery or severe trauma within 3 months (avoid if within 6 weeks); traumatic or protracted cardiopulmonary resuscitation, organ biopsy or lithotripsy within last 2 weeks; risk of bleeding including peptic ulcer within 3 months; acute pericarditis, aortic dissection, haemorrhagicretinopathy, vasculitis, haematuria, faecal occult blood, severe heart failure, cardiogenic shock, anaemia; puncture of non-compressible vessel within 24 hours; concomittant drugs that increase risk of bleeding (including within 48 hours after thrombolytic); monitor platelet count, haemoglobin and haematocrit before treatment, 2-6 hours after start of treatment and then atleast once daily ; discontinue if thrombolytic therapy, intra-aortic balloon pump or emergency cardiac surgery necessary; discontinue immediately if serious bleeding uncontrolled by pressure occurs; pregnancy (use only if potential benefits outweigh risk) .
High Risk Groups
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Dosage
Brands
Community Contribution
Do you know any authentic drug which is not listed here? Please let us know.